In this guest blog, Dale Greenwood, mental health lead for East London NHS Foundation Trust, shares how his trust implemented a digital innovation to support children's mental health. These cookies ...

Around 1,500 people with multiple myeloma are set to benefit from the treatment, which combines belantamab mafodotin (brand name Blenrep) with bortezomib and dexamethasone.

More than 30,000 children and young people are living with type 1 diabetes in England. Usual management involves finger prick testing and injecting insulin multiple times a day. HCL systems remove the ...

The benefits of Alzheimer’s treatments donanemab and lecanemab remain too small to justify the additional costs ...

The draft guideline recommends medicines be given up to a year earlier - helping people live well for longer. We’re updating the recommendations for drug treatments in our clinical guideline on the ...

Evidence-based recommendations on nivolumab (Opdivo) plus ipilimumab (Yervoy) for untreated unresectable or metastatic colorectal cancer with high microsatellite instability in adults.. Last reviewed: ...

Evidence-based recommendation on linzagolix (Yselty) for treating symptoms of endometriosis in adults of reproductive age.. Last reviewed: 04 June 2025 Next review: This guidance will be reviewed if ...

Evidence-based recommendations on efgartigimod (Vyvgart) for treating antibody-positive generalised myasthenia gravis in adults.. Last reviewed: 04 June 2025 Next review: This guidance will be ...

Programme director for Healthtech strategy and development. Imagine a future where groundbreaking health technologies reach NHS patients in a matter of months rather than years. Where innovative ...

Evidence-based recommendations on somapacitan (Sogroya) for treating growth hormone deficiency in people 3 to 17 years.. Last reviewed: 03 June 2025 Next review: This guidance will be reviewed if ...

We're joined by 2 members of the guideline committee, health visitor Karen McLean and health psychologist Vivien Swanson, to discuss updates to our guideline supporting nutrition and weight management ...

Somapacitan can be used, within its marketing authorisation, as an option to treat growth failure caused by growth hormone deficiency in people 3 to 17 years. Somapacitan can be used if the company ...